collection
MENU ▼
Read by QxMD icon Read
search

MMCBreast Collection

shared collection
376 papers 100 to 500 followers
https://www.readbyqxmd.com/read/29663173/current-status-of-neoadjuvant-endocrine-therapy-in-early-stage-breast-cancer
#1
REVIEW
Tomás Reinert, Rodrigo Gonçalves, Matthew J Ellis
Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer...
April 16, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29656345/update-on-the-treatment-of-early-stage-triple-negative-breast-cancer
#2
REVIEW
Priyanka Sharma
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is associated with poor long-term outcomes compared to other breast cancer subtypes. Currently, chemotherapy remains the main modality of treatment for early-stage TNBC, as there is no approved targeted therapy for this subtype. The biologic heterogeneity of TNBC has hindered the development and evaluation of novel agents, but recent advancements in subclassifying TNBC have paved the way for further investigation of more effective systemic therapies, including cytotoxic and targeted agents...
April 14, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29656223/delay-of-adjuvant-radiotherapy-due-to-postoperative-complications-after-oncoplastic-breast-conserving-surgery
#3
Nadine S Hillberg, Marleen A J Meesters-Caberg, Jop Beugels, Bjorn Winkens, Yvonne L J Vissers, Tom J M van Mulken
BACKGROUND: In the past a mastectomy was the first approach of treating breast cancer. Oncoplastic techniques combined with breast conserving surgery (BCS) and radiotherapy has become an alternative to mastectomy in patients with non-metastasized breast cancer. The aim of this study was to analyse the amount and types of complications occurring after oncoplastic BCS before and after adjuvant radiotherapy and the delay of adjuvant therapy due to the complications. METHOD: A retrospective study based on all patients who received immediate oncoplastic BCS by a plastic surgeon at two medical hospitals in The Netherlands between 2013 and 2015...
April 12, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29644491/update-on-parp-inhibitors-in-breast-cancer
#4
REVIEW
Alexandra S Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung-Min Lee
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progression-free survival improvement with PARPi compared to physician's choice single agent chemotherapy in metastatic gBRCAm breast cancer...
April 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29625911/specialized-second-opinion-interpretations-of-breast-imaging-impact-on-additional-workup-and-management
#5
R Jared Weinfurtner, Bethany Niell, Yasmin Mekhail, Emily Aguila, Leena Kamat
BACKGROUND: Women with breast imaging often seek second opinions at tertiary care centers. Our study measures the frequency of discrepancy between initial and second opinion breast imaging recommendations and evaluates the impact on patient management. MATERIALS AND METHODS: A retrospective chart review was conducted on 504 consecutive patients with second opinion breast radiology interpretations performed by 6 sub-specialized breast radiologists at a dedicated cancer center from January 1, 2014 through September 1, 2014...
March 16, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29620792/risk-reducing-mastectomy-for-the-prevention-of-primary-breast-cancer
#6
REVIEW
Nora E Carbine, Liz Lostumbo, Judi Wallace, Henry Ko
BACKGROUND: Recent progress in understanding the genetic basis of breast cancer and widely publicized reports of celebrities undergoing risk-reducing mastectomy (RRM) have increased interest in RRM as a method of preventing breast cancer. This is an update of a Cochrane Review first published in 2004 and previously updated in 2006 and 2010. OBJECTIVES: (i) To determine whether risk-reducing mastectomy reduces death rates from any cause in women who have never had breast cancer and in women who have a history of breast cancer in one breast, and (ii) to examine the effect of risk-reducing mastectomy on other endpoints, including breast cancer incidence, breast cancer mortality, disease-free survival, physical morbidity, and psychosocial outcomes...
April 5, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29621695/incidence-of-isolated-local-breast-cancer-recurrence-and-contralateral-breast-cancer-a-systematic-review
#7
REVIEW
Inge Spronk, François G Schellevis, Jako S Burgers, Geertruida H de Bock, Joke C Korevaar
An increasing number of women is surviving breast cancer and due to that at risk of developing an isolated ipsilateral breast tumor recurrence (IBTR) or a contralateral breast cancer (CBC). Patients' main concern is cancer recurrence. Patient counseling on breast cancer recurrence is challenging. In order to provide healthcare professionals and patients more guidance, a systematic literature review of the incidence of isolated IBTR and CBC in women diagnosed with early invasive breast cancer was performed. Medline, EMBASE and the Cochrane Library were searched from 2000 until October 2015...
April 2, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29605705/nsqip-analysis-of-axillary-lymph-node-dissection-rates-for-breast-cancer-implications-for-resident-and-fellow-participation
#8
Nadia F Nocera, Bryan J Pyfer, Lucy M De La Cruz, Abhishek Chatterjee, Paul T Thiruchelvam, Carla S Fisher
INTRODUCTION: Management of the axilla in invasive breast cancer (IBC) has shifted away from more radical surgery such as axillary lymph node dissection (ALND), towards less invasive procedures, such as sentinel lymph node biopsy. Because of this shift, we hypothesize that there has been a national downward trend in ALND procedures, subsequently impacting surgical trainee exposure to this procedure using the ACS-NSQIP database to evaluate this. METHODS: Women with IBC were identified in the ACS-NSQIP database from 2007 to 2014...
March 28, 2018: Journal of Surgical Education
https://www.readbyqxmd.com/read/29605078/pre-surgical-chemotherapy-for-breast-cancer-may-be-associated-with-improved-outcomes
#9
Madeline Cook, Nathalie Johnson
BACKGROUND: Historical studies suggest no difference in disease outcome between neoadjuvant and adjuvant approaches in breast cancer. We hypothesize neoadjuvant chemotherapy (NCT) may offer several benefits, possibly improving quality of life outcomes. METHODS: Retrospective review of Tumor Registry data of breast cancer patients from 2011 to 2015. Pathologists reviewed cases from 2012 to 2013 to provide additional RCB (residual cancer burden) scores. RESULTS: From 2011 to 2015 there were 2707 breast cancer cases and 455 patients received NCT...
March 16, 2018: American Journal of Surgery
https://www.readbyqxmd.com/read/29603132/meta-analysis-of-neoadjuvant-therapy-and-its-impact-in-facilitating-breast-conservation-in-operable-breast-cancer
#10
REVIEW
A Karakatsanis, M K Tasoulis, F Wärnberg, G Nilsson, F MacNeill
BACKGROUND: Neoadjuvant therapy (NAT) for operable breast cancer may facilitate more breast-conserving surgery (BCS). It seems, however, that this benefit is not being realized fully. METHODS: A systematic review of the literature was performed. RCTs were included. The criteria for inclusion were: documentation of surgical assessment before and after NAT, surgery performed (BCS or mastectomy), and clinical and pathological responses. RESULTS: A total of 1452 patients from seven RCTs met the inclusion criteria...
April 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29574393/the-performance-of-one-step-nucleic-acid-amplification-assay-for-intraoperative-detection-of-sentinel-lymph-node-macrometastasis-in-breast-cancer-an-updated-meta-analysis
#11
Fang Shi, Zhenzhen Liang, Qian Zhang, Chunpeng Wang, Xin Liu
BACKGROUND: One-step nucleic acid amplification (OSNA) assay is a molecular diagnostic method for intraoperative detection of lymph node metastasis by amplifying cytokeratin 19 mRNA. We aim to further evaluate the performance of OSNA assay for the intraoperative diagnosis of sentinel lymph node metastasis in breast cancer. METHODS: PubMed, Cochrane Library, Web of Science databases were searched to retrieve related literature published up until December 2017. This meta-analysis was performed using a random-effects model...
March 22, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29564588/most-breast-cancer-patients-with-t1-2-tumors-and-one-to-three-positive-lymph-nodes-do-not-need-postmastectomy-radiotherapy
#12
Shirin Muhsen, Tracy-Ann Moo, Sujata Patil, Michelle Stempel, Simon Powell, Monica Morrow, Mahmoud El-Tamer
BACKGROUND/OBJECTIVE: Guidelines concur that postmastectomy radiation therapy (PMRT) in T1-2 tumors with one to three positive (+) lymph nodes (LNs) decreases locoregional recurrence (LRR) but advise limiting PMRT to patients at highest risk to balance against potential harms. In this study, we identify the risks of LRR after mastectomy in patients with T1-2N1 disease, treated with modern chemotherapy, and identify predictors of LRR when omitting PMRT. METHODS: Patients with T1-2N1 breast cancer undergoing mastectomy between 1995 and 2006 were categorized by receipt of PMRT...
March 21, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29525735/outcomes-in-real-world-practice-are-different-than-cooperative-trial-for-elderly-patients-with-early-breast-cancer-treated-with-adjuvant-radiation-therapy
#13
Quyen D Chu, Meijiao Zhou, Prakash Peddi, Kaelen L Medeiros, Xiao-Cheng Wu
BACKGROUND: The Cancer and Leukemia Group B 9,343 demonstrated that postoperative radiation can be safely omitted in women ≥70 years who underwent breast-conserving therapy for clinical stage I (T1N0M0) estrogen receptor positive breast cancer treated with antihormonal therapy. Whether such results are observed in real-world population is unknown. In this hospital-based data, we report the survival outcomes of patients who received adjuvant radiation therapy versus those who did not...
March 7, 2018: Surgery
https://www.readbyqxmd.com/read/29555055/surgical-management-of-the-axilla-in-early-breast-cancer
#14
Ismail Jatoi, John R Benson
No abstract text is available yet for this article.
February 2018: Current Problems in Surgery
https://www.readbyqxmd.com/read/29529454/are-we-ready-for-the-challenge-of-implementing-risk-based-breast-cancer-screening-and-primary-prevention
#15
REVIEW
Linda Rainey, Daniëlle van der Waal, Anna Jervaeus, Yvonne Wengström, D Gareth Evans, Louise S Donnelly, Mireille J M Broeders
BACKGROUND: Increased knowledge of breast cancer risk factors provides opportunities to shift from a one-size-fits-all screening programme to a personalised approach, where screening and prevention is based on a woman's risk of developing breast cancer. However, potential implementation of this new paradigm could present considerable challenges which the present review aims to explore. METHODS: Bibliographic databases were searched to identify studies evaluating potential implications of the implementation of personalised risk-based screening and primary prevention for breast cancer...
March 9, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29524664/do-all-positive-margins-in-breast-cancer-patients-undergoing-a-partial-mastectomy-need-to-be-resected
#16
Anees B Chagpar, Theodore N Tsangaris, Donald R Lannin
BACKGROUND: Positive margins have been reported in 20-40% of patients undergoing a partial mastectomy (PM), often resulting in re-excision. How often the re-excision yields further cancer and whether there are predictors of residual disease remains unknown. STUDY DESIGN: Patients who had a positive margin (defined as tumor at ink for patients with invasive disease or within 1 mm for patients with DCIS) in the SHAVE trial prior to randomization were evaluated to determine the rate of additional disease either in cavity shave margins (CSM) or at re-excision...
March 7, 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29526019/systematic-versus-sentinel-lymph-node-driven-axillary-lymph-node-dissection-in-clinically-node-negative-patients-with-operable-breast-cancer-results-of-the-gf-gs01-randomized-trial
#17
P Roy, A Leizorovicz, R Villet, C Mercier, J Y Bobin
PURPOSE: Sentinel-lymph-node (SLN) resection seems to minimize systematic axillary-lymph-node dissection (sALND) side effects in operated breast cancer patients. We explored whether SLN resection achieves similar therapeutic outcomes as sALND but with fewer side effects. METHODS: A randomized, controlled, open-label trial with parallel-group design compared sALND restricted to cases with positive SLN biopsy (test arm, n = 774) versus SLN biopsy followed by sALND (control arm, n = 770)...
March 10, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29520654/the-21-gene-recurrence-score-in-male-breast-cancer
#18
Gulisa Turashvili, Monica Gonzalez-Loperena, Edi Brogi, Maura Dickler, Larry Norton, Monica Morrow, Hannah Y Wen
BACKGROUND: Given the limited data, systemic treatment of male breast cancer has been extrapolated from female patients. The 21-gene recurrence score (RS) assay estimates the risk of distant recurrence and chemotherapy benefit in early-stage, ER+/HER2- female breast cancer. We assessed the association between RS and type of treatment in male breast cancer. METHODS: We identified male patients with ER+/HER2- breast cancer and available RS results treated at our institution in 2006-2016...
March 8, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29516374/use-of-adjuvant-chemotherapy-in-hormone-receptor-positive-breast-cancer-patients-with-or-without-the-21-gene-expression-assay
#19
Soo Jin Park, Moo Hyun Lee, Sun-Young Kong, Mi Kyung Song, Jungnam Joo, Youngmee Kwon, Eun-Gyeong Lee, Jai Hong Han, Sung Hoon Sim, So-Youn Jung, Seeyoun Lee, Keun Seok Lee, In Hae Park, Eun Sook Lee
PURPOSE: We assessed the use of chemotherapy in breast cancer patients to investigate the factors that changed trends in chemotherapy following the adoption of the 21-gene expression assay in tumor genomic profiling. METHODS: Our study used 2033 patients from the National Cancer Center in Korea diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (tumor size of 0.5 cm or larger and 0-3 node metastases) from 2010 to 2015...
March 8, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29511992/major-reduction-in-axillary-lymph-node-dissections-after-neoadjuvant-systemic-therapy-for-node-positive-breast-cancer-by-combining-pet-ct-and-the-mari-procedure
#20
M E M van der Noordaa, F H van Duijnhoven, M E Straver, E J Groen, M Stokkel, C E Loo, P H M Elkhuizen, N S Russell, M T F D Vrancken Peeters
BACKGROUND: Axillary lymph node dissection (ALND) is frequently performed for node-positive (cN+) breast cancer patients. Combining positron emission tomography/computed tomography (PET/CT) before-NST and the MARI (marking axillary lymph nodes with radioactive iodine seeds) procedure after neoadjuvant systemic therapy (NST) has the potential for avoiding unnecessary ALNDs. This report presents the results from implementation of this strategy. METHODS: All breast cancer patients treated with NST at the Netherlands Cancer Institute who underwent a PET/CT and the MARI procedure from July 2014 to July 2017 were included in the study...
March 6, 2018: Annals of Surgical Oncology
label_collection
label_collection
6331
1
2
2018-03-09 13:45:33
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"